...Treat impulsive aggression in patients with ADHD Phase III data 2H19 Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) SPN-812...

...NASDAQ:SUPN) Molindone Aggression in patients with ADHD Phase III data Mid-2019 Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) SPN-812...

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said on Dec. 20 that both doses of SPN-812 met the primary...
...to receive placebo or once-daily 200 or 400 mg oral SPN-812. On the primary endpoint, SPN-812...
...SPN-812 -- Study P304 in adolescents with ADHD. Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Product: SPN-812...

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said SPN-812 met the primary endpoint in the Phase III P301 and...
...patients ages 6-11, respectively, to receive placebo or once-daily oral SPN-812. On P301's primary endpoint, SPN-812...
...respectively, of SPN-812 to treat adolescents with ADHD. Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Product: SPN-812...

...in 222 ADHD patients ages 6-12 showed that once-daily 200, 300 and 400 mg oral SPN-812...
...total score from baseline to week 8 vs. placebo. Specifically, 200, 300 and 400 mg SPN-812...
...mg SPN-812 for 5 weeks following a 3-week titration period. The 3 highest doses of SPN-812...

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said the three highest doses of SPN-812 met the primary endpoint of...
...inhibitor next year. The trial evaluated once-daily 100, 200, 300 and 400 mg doses of SPN-812...
...titration period in 222 children ages six to 12 with ADHD. The lowest dose of SPN-812...

...double-blind, placebo-controlled, U.S. Phase IIa trial in 52 adults with ADHD showed that thrice-daily oral SPN-812...
...5 weeks was well tolerated and met the primary endpoint of safety. On secondary endpoints, SPN-812...
...show statistical significance on any of the endpoints. Supernus Pharmaceuticals Inc. , Rockville, Md. Product: SPN-812...

...Supernus Pharmaceuticals Inc. (Rockville, Md.) said thrice-daily oral SPN-812 for five weeks was well tolerated and...
...safety in a Phase IIa trial to treat 52 adults with ADHD. On secondary endpoints, SPN-812...
...said the trial was not designed to show statistical significance on any of the endpoints. SPN-812...